A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome

Hospital Authority, Hong Kong

Status: Unknown

Conditions: Severe Acute Respiratory Syndrome

Treatments: Drug: Lopinavir / Ritonavir plus Ribavirin

Study type: Interventional

Funder types: Other

Identifiers

NCT00578825

HARECCTR0500028

NTWC/CREC/349/05

KW/FR/04-009

Details and patient eligibility

About

The study aims to examine whether the combination of Lopinavir/Ritonavir plus Ribavirin for treatment of severe acute respiratory syndrome (SARS) is superior to placebo.

Enrollment: 340 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female over the age of 18 with a diagnosis of SARS and with valid consent will be recruited.

Exclusion criteria

• Subjects with medical conditions that makes the prescription of study medications unsafe are excluded.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind